Assessment of Population Immunity to SARS-CoV-2 Virus in the Rostov Region

Попова, А. Ю.; Ежлова, Е. Б.; Мельникова, А. А.; Носков, А. К.; Ковалев, Е. В.; Карпущенко, Г. В.; Лялина, Л. В.; Смирнов, В. С.; Чемисова, О. С.; Тришина, А. В.; Березняк, Елена Александровна; Воловикова, Софья; Стенина, Снежана; Янович, Е. Г.; Мелоян, М. Г.; Асмолова, Н. Ю.; Усова, А. А.; Слись, Сергей; Тотолян, Арег А.

doi:10.21055/0370-1069-2020-4-117-124

Cited by 7 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Perhaps the publication of this English version of the work will help to fill in information gaps to some extent. Further, it is worth mentioning that a large group of authors have already published 16 articles in Russian publications under the auspices of the head of Rospotrebnadzor, Professor A. Y. Popova [ 17 , 18 , 19 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 ].…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic

Popova

Смирнов

Андреева

et al. 2021

Viruses

Self Cite

View full text Add to dashboard Cite

The SARS-CoV-2 pandemic, which came to Russia in March 2020, is accompanied by morbidity level changes and can be tracked using serological monitoring of a representative population sample from Federal Districts (FDs) and individual regions. In a longitudinal cohort study conducted in 26 model regions of Russia, distributed across all FDs, we investigated the distribution and cumulative proportions of individuals with antibodies (Abs) to the SARS-CoV-2 nucleocapsid antigen (Ag), in the period from June to December 2020, using a three-phase monitoring process. In addition, during the formation of the cohort of volunteers, the number of seropositive convalescents, persons who had contact with patients or COVID-19 convalescents, and the prevalence of asymptomatic forms of infection among seropositive volunteers were determined. According to a uniform methodology, 3 mL of blood was taken from the examined individuals, and plasma was separated, from which the presence of Abs to nucleocapsid Ag was determined on a Thermo Scientific Multiascan FC device using the “ELISA anti-SARS-CoV-2 IgG” reagent set (prod. Scientific Center for Applied Microbiology and Biotechnology), in accordance with the developer’s instructions. Volunteers (74,158) were surveyed and divided into seven age groups (1–17, 18–29, 30–39, 40–49, 59–59, 60–69, and 70+ years old), among whom 14,275 were identified as having antibodies to SARS-CoV-2. The average percent seropositive in Russia was 17.8% (IQR: 8.8–23.2). The largest proportion was found among children under 17 years old (21.6% (IQR: 13.1–31.7). In the remaining groups, seroprevalence ranged from 15.6% (IQR: 8–21.1) to 18.0% (IQR: 13.4–22.6). During monitoring, three (immune) response groups were found: (A) groups with a continuous increase in the proportion of seropositive; (B) those with a slow rate of increase in seroprevalence; and (C) those with a two-phase curve, wherein the initial increase was replaced by a decrease in the percentage of seropositive individuals. A significant correlation was revealed between the number of COVID-19 convalescents and contact persons, and between the number of contacts and healthy seropositive volunteers. Among the seropositive volunteers, more than 93.6% (IQR: 87.1–94.9) were asymptomatic. The results show that the COVID-19 pandemic is accompanied by an increase in seroprevalence, which may be important for the formation of herd immunity.

show abstract

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic

Popova

Смирнов

Андреева

et al. 2021

Viruses

Self Cite

View full text Add to dashboard Cite

show abstract

Features of developing SARS-CoV-2 nucleocapsid protein population-based seroprevalence during the first wave of the COVID-19 epidemic in the Russian Federation

Попова

Андреева

Бабура

et al. 2021

Russian Journal of Infection and Immunity

Self Cite

View full text Add to dashboard Cite

The novel coronavirus (SARS-CoV-2) pandemic, dubbed COVID-19, has become one of the most serious challenges for human populations in the vast majority of countries worldwide. Rapid spreading and increased mortality related to it required new approaches to manage epidemic processes on a global scale. One of such approaches was based on analyzing SARS-CoV-2 seroprevalence associated with COVID-19. Our aim was to summarize the results on assessing seroprevalence to the SARS-CoV-2 nucleocapsid antigen (Nc) in residents from 26 regions of the Russian Federation, carried out during the first wave of the COVID-19 epidemic.Materials and methods. Seroprevalence distribution was examined in 26 model regions of the Russian Federation according to the unified method developed by the Rospotrebnadzor with the participation of the Federal State Institution Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology. Such approach implied formation of a group of volunteer subjects in model geographic region who were tested by ELISA for anti-Nc serum antibody level in peripheral blood. Analyzed primary data obtained in separate regions were either accepted for publication or released.Results. The current paper finalizes the data obtained in all 26 regions of the Russian Federation. The total SARS-CoV-2 seroprevalence was 19.5 (10.0–25.6)% with the maximum and minimum value found in the Kaliningrad Region and the Republic of Crimea, respectively (50.2% vs. 4.3%). A pattern of age-related seroprevalence distribution indicates insignificant predominance of seroprevalence among subjects of 1–17 years old: 22.1 (13.1–31.8)%. Among COVID-19 convalescents positive for SARS-CoV Nc antibodies it reached 60.0 (40.0–73.3)%. The number of contact persons comprised 6285 subjects or 8.5% of total volunteer cohort, with the level of seroprevalence reaching up to 25.3 (17.95–35.8)%. A direct correlation was revealed between levels of seroprevalence in convalescent and contact volunteers. In addition, the reproductive number for SARS-CoV was calculated comprising 5.8 (4.3–8.5) suggesting that one convalescent subject can infect at least 4 healthy individuals. A high level of asymptomatic forms of COVID-19 among seropositive subjects was confirmed empirically comprising up to 93.6 (87.1–94.9)%.Conclusion. A single cross-sectional study performed during 2020 June–August timeframe allowed to assess pattern of sex- and agerelated COVID-19 seroprevalence for general population in 26 Russian Federation regions. The data obtained may serve as a basis for the longitudinal cohort investigation with serial subject sampling. The timing and duration of study will be determined by dynamics of ongoing COVID-19 epidemic.

show abstract

Methodology for assessing herd immunity to the SARS-CoV-2 virus in the context of the COVID-19 pandemic

Попова

Тотолян

2021

Russian Journal of Infection and Immunity

Self Cite

View full text Add to dashboard Cite

Serological monitoring of the study of population immunity to the SARS-CoV-2 virus in the context of COVID-19 pandemic is a necessary component in epidemiological surveillance, since population epidemiological wellbeing in a context of COVID-19 is determined by state of population immunity to the SARS-CoV-2 virus. The population herd immunity is the limiting factor in spread of the SARS-CoV-2 virus. Information on the state of population immunity is necessary to make a forecast for development of epidemiological situation, as well as to plan measures for specific and non-specific prevention of COVID-19. In this regard, the study of population immunity during the pandemic is necessary to predict development of the epidemic and identify features of epidemic process in any certain region and in the country in general. In May 2020, the Rospotrebnadzor program “Assessment of population immunity to the SARS-CoV-2 virus in the population of the Russian Federation in the context of the COVID-19 pandemic” was developed taking into account WHO recommendations in the format of a longitudinal cohort study with age stratification: at the first stage, a cohort of volunteers is formed; at the second and subsequent stages, the cohort of volunteers formed at the first stage is subject to examination; the number of stages depends on the epidemiological situation. In addition to age-related randomization while forming a cohort, at the first stage, the principle of population coverage uniformity was observed, the participation of volunteers from one institution was excluded, and the use of donated blood or patient blood from medical organizations was excluded. The survey was carried out among 7 age groups of healthy children and adults, regardless present or absent previous COVID-19 disease. Due to the fact that the population study is carried out in the context of COVID-19 pandemic, the optimal timing for collecting biomaterial at each stage is no more than 5–7 days. Questioning, selection of volunteers, their registration for blood donation, as well as processing of the results at the first stage, as well as the implementation of the second and subsequent stages of the Program are carried out only by using cloud service technology. This Program and the technology for its implementation have been successfully tested in 26 regions of the Russian Federation during the implementation of four stages from June 2020 to March 2021. Thus, at present, Rospotrebnadzor has developed a methodology and created an effectively working system of serological monitoring to assess level of herd immunity in different regions of the Russian Federation to predict the epidemiological situation, develop recommendations, and plan vaccination.

show abstract

Assessment of Population Immunity to SARS-CoV-2 Virus in the Rostov Region

Cited by 7 publications

References 9 publications

SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic

SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic

Features of developing SARS-CoV-2 nucleocapsid protein population-based seroprevalence during the first wave of the COVID-19 epidemic in the Russian Federation

Methodology for assessing herd immunity to the SARS-CoV-2 virus in the context of the COVID-19 pandemic

Contact Info

Product

Resources

About